Literature DB >> 26872012

Primary Pseudomyogenic Hemangioendothelioma of Bone.

Alero Inyang1, Fredrik Mertens, Florian Puls, Vaiyapuri Sumathi, Carrie Inwards, Andrew Folpe, Cheng-Han Lee, Yaxia Zhang, Pennie Symmans, Brian Rubin, Gunnlaugur P Nielsen, Van-Hung Nguyen, Andrew E Rosenberg.   

Abstract

Pseudomyogenic hemangioendothelioma (PMH) is a well-recognized neoplasm that usually arises in the soft tissue; concurrent bone involvement occurs in 24% of cases. PMH of bone without soft tissue involvement is rare. We describe the clinicopathologic findings of 10 such cases, the largest series reported to date. The study included 9 male and 1 female patient; their ages ranged from 12 to 74 years (mean 36.7 y). All patients had multiple tumors with a distinct regional distribution: 45% restricted to the lower extremity; 25% to the spine and pelvis; and 15% to the upper extremity. On imaging studies the tumors were well circumscribed and lytic. The neoplasms were composed of spindled cells arranged in intersecting fascicles with scattered epithelioid cells; epithelioid cells predominated in 3 cases. The neoplastic cells contained abundant densely eosinophilic cytoplasm and vesicular nuclei. There was limited cytologic atypia and necrosis, few mitoses (0 to 2/10 high-power fields), and inconspicuous stroma. Unique findings included abundant intratumoral reactive woven bone and hemorrhage with numerous osteoclast-like giant cells. Immunohistochemically, most tumors were positive for keratin, ERG, and CD31; CD34 was negative. The balanced t(7:19)(q22;13) translocation was documented in 3 cases. Follow-up is limited, but no patient developed documented visceral dissemination, and all have stable or progressive osseous disease. PMH exclusively involving bone is rare. It is multicentric, often involves the lower extremity, and has unusual morphology. The differential diagnosis includes epithelioid vascular neoplasms, giant cell tumor, bone forming neoplasms, and metastatic carcinoma. Because of its rarity, unusual presentation, and morphology, accurate diagnosis can be challenging.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26872012     DOI: 10.1097/PAS.0000000000000613

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  12 in total

1.  The clinicopathological spectrum of pseudomyogenic hemangioendothelioma: report of an additional series with review of the literature.

Authors:  Yuefang Sun; Ming Zhao; I Weng Lao; Lin Yu; Jian Wang
Journal:  Virchows Arch       Date:  2020-01-24       Impact factor: 4.064

Review 2.  [Updates to the WHO classification of bone tumours].

Authors:  G Jundt
Journal:  Pathologe       Date:  2018-03       Impact factor: 1.011

Review 3.  Malignant mesenchymal neoplasms of the dermis and subcutis mimicking benign lesions: a case-based review.

Authors:  Thomas Mentzel; Thomas Brenn
Journal:  Virchows Arch       Date:  2017-07-12       Impact factor: 4.064

4.  Lower-Extremity Pseudomyogenic Hemangioendothelioma on Bone Scintigraphy and PET/CT.

Authors:  Simone Krebs; Serena Monti; Natasha Lewis; Alessandro Luciano; Lapo Rastrelli; Lorenzo Mannelli
Journal:  Clin Nucl Med       Date:  2017-05       Impact factor: 7.794

5.  Primary vascular bone tumors in the spine: a challenge for pathologists and spine oncology surgeons.

Authors:  Stefano Boriani; Riccardo Cecchinato; Alberto Righi; Stefano Bandiera; Angelo Paolo Dei Tos; Riccardo Ghermandi; Alessandro Gasbarrini
Journal:  Eur Spine J       Date:  2019-03-21       Impact factor: 3.134

6.  Pseudomyogenic hemangioendothelioma: A misleading vascular tumor.

Authors:  Farah Sassi; Ghada Sahraoui; Lamia Charfi; Olfa Jaidane; Karima Mrad; Raoudha Doghri
Journal:  Int J Surg Case Rep       Date:  2022-09-12

7.  Expanding the Spectrum of Genetic Alterations in Pseudomyogenic Hemangioendothelioma With Recurrent Novel ACTB-FOSB Gene Fusions.

Authors:  Narasimhan P Agaram; Lei Zhang; Paolo Cotzia; Cristina R Antonescu
Journal:  Am J Surg Pathol       Date:  2018-12       Impact factor: 6.394

Review 8.  Pseudomyogenic hemangioendothelioma with bone and soft tissue involvement with favorable response to pamidronate: a case report and systematic review of the literature.

Authors:  María Lorena Brance; Nicolás M Cóccaro; Pablo Roitman; Alejandro Castiglioni; Florencia Agostinis; Mariel Spense; Bárbara Scheitlin; Nicholas Rene; Lucas R Brun
Journal:  Arch Osteoporos       Date:  2022-02-01       Impact factor: 2.617

9.  Pseudomyogenic hemangioendothelioma-A case report and review of the literature.

Authors:  Saeed Dianat; Hira Yousaf; Paari Murugan; Shelly Marette
Journal:  Radiol Case Rep       Date:  2019-08-06

10.  Diagnostic utility of FOSB immunohistochemistry in pseudomyogenic hemangioendothelioma and its histological mimics.

Authors:  Shintaro Sugita; Hiroshi Hirano; Noriaki Kikuchi; Terufumi Kubo; Hiroko Asanuma; Tomoyuki Aoyama; Makoto Emori; Tadashi Hasegawa
Journal:  Diagn Pathol       Date:  2016-08-11       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.